NCT01856543View on ClinicalTrials.gov

Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation

PHASE3CompletedINTERVENTIONAL
Enrollment

143

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Invasive Breast Cancer
Interventions
OTHER

Eucerin

OTHER

Mometasone Furoate 0.1%

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

10604

Memorial Sloan Kettering West Harrison, Harrison

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Commack, Commack

07939

Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01856543 - Mometasone Furoate 0.1% Versus Eucerin on Moderate to Severe Skin Toxicities in Breast Cancer Patients Receiving Postmastectomy Radiation | Biotech Hunter | Biotech Hunter